Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-TXNDC9, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TXNDC9 also known as Thioredoxin Domain Containing 9 or ERdj5 functions as a protein disulfide isomerase involved in the reduction and isomerization of disulfide bonds. This protein weighs approximately 56 kDa and exhibits expression mostly in the endoplasmic reticulum of various cells. TXNDC9 with its oxidoreductase activity plays an important role in maintaining protein folding homeostasis and cellular redox balance. Researchers have identified it as a central player in protein quality control mechanisms.
Biological function summary
TXNDC9 assists in the protein folding process within the endoplasmic reticulum acting as part of larger protein complexes that include other chaperones. It particularly engages in helping misfolded proteins to attain their correct conformation contributing significantly to the protein folding machinery. Additionally TXNDC9 interacts with client proteins guiding their correct structural organization and preventing the accumulation of misfolded proteins that could be harmful to the cell.
Pathways
TXNDC9 occupies a significant position in the endoplasmic reticulum-associated degradation (ERAD) pathway and the unfolded protein response (UPR) pathway. It interacts with proteins such as Ero1 and BiP to ensure proper degradation of misfolded proteins and maintain cellular stress responses. In the ERAD pathway TXNDC9 acts to identify and prepare proteins for degradation while in the UPR pathway it supports roles that mitigate stress signals caused by accumulated unfolded proteins.
TXNDC9 involvement links to neurodegenerative diseases and certain cancers. Its role in maintaining protein homeostasis reflects connections to Alzheimer's disease where protein misfolding aggregates contribute to pathology. Similarly aberrant TXNDC9 function associates with tumor development in some cancers due to its involvement with cellular redox status and growth control mechanisms. In these contexts TXNDC9 may interact with proteins like Amyloid-beta in Alzheimer's and could influence oncogenic pathways through interactions with tumor-suppressor proteins.
